Phylogica licenses technology to Janssen Biotech, Inc.
Advertisement
Phylogica Ltd announced a Collaboration and Option agreement with Janssen Biotech, Inc., to discover new classes of drugs derived from Phylogica’s Phylomer® peptide platform.
In the initial stage of the collaboration, Phylogica will identify cell-penetrating Phylomer® peptides. Under the terms of the agreement, Janssen could develop Phylomer®-based drug candidates and has the option to expand the scope of the collaboration to include additional cell-specific Phylomers® for the development of a further ten drug candidates.
Under the terms of this multi-product agreement, Phylogica will receive an initial technology access fee as well as research funding over the first 18 months of the collaboration. Pending ongoing discussions with Janssen regarding commercial terms, Phylogica could receive further research funding, license fees, milestone payments and royalties on worldwide sales.
Dr Paul Watt, Phylogica’s Chief Executive Officer, said: "We are delighted to be working with Janssen, which adds to our growing list of partners. This deal reflects our commitment to exploit the potential of Phylomers to address challenging disease targets with the aim of delivering new standards of care for patients. We look forward to working in partnership with Janssen to advance multiple Phylomer-based drug candidates. This agreement provides further validation of our world-leading Phylomer technology for peptide drug discovery.”
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Biotools, B & M Labs, S.A. - Madrid, Spain
Structure of key complex in the immune system - New study reveals the structure of complement component C1 – a target for complement-mediated diseases including strokes and heart attacks
Computer tool analyzes in detail genetic alterations in the genome of cancer cells - Developed by CSIC, CiberAMP allows establishing direct correlations between changes in the number of gene copies in tumor cells and their expression levels
Proteros and CHDI Foundation, Inc. establish discovery services collaboration to address Huntington’s disease
Horizon Discovery Group plc, Centre for Process Innovation and University of Manchester Awarded £1.67M - Consortium to receive funding to develop enhanced biomanufacturing platforms based on the Company’s CHO cell line and gene editing platform
